Genosco

Executive Summary

Genosco is a private, clinical-stage biotechnology company headquartered in Cambridge, MA, focused on developing highly selective kinase inhibitors and degraders for oncology and fibrotic diseases. Founded in 2018, the company leverages its proprietary GENO-K™ and GENO-D™ platforms to identify rare kinase sequences and rapidly generate novel small molecule compounds. By targeting kinases with high selectivity, Genosco aims to address significant unmet medical needs, particularly in cancers and fibrotic conditions where current therapies have limited efficacy or tolerability. The company is currently advancing its lead candidate through Phase 1 clinical trials, with an emphasis on tumor types driven by specific kinase alterations. Its platform approach also supports the discovery of protein degraders, expanding its therapeutic reach. As a private entity, Genosco has not disclosed total funding or valuation, but its presence in the competitive Cambridge biotech hub and focus on kinase modulation positions it within a well-established drug development space. The company's early-stage status implies that near-term value inflection points will depend on clinical data, regulatory milestones, and potential partnering activities.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 clinical data readout for lead kinase inhibitor candidate55% success
• Q3 2026IND filing for second-generation degrader program40% success
• Q4 2026Partnership or licensing deal for platform technology35% success